Voyager Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(amounts in thousands, except share data)

Accumulated
Additional · Other
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balance at December 31, 2025	59,047,860	$	59	$	641,895	$	32	$	(445,905)	$	196,081
Exercises of stock options	87,081		—		294		—		—		294
Vesting of restricted stock units	545,015		—		—		—		—		—
Issuance of common stock from at-the-market sales agreement, net of issuance costs	630,570		1		3,037		—		—		3,038
Stock-based compensation expense	—		—		2,488		—		—		2,488
Unrealized loss on available-for-sale securities, net of tax	—		—		—		(295)		—		(295)
Net loss	—		—		—		—		(27,937)		(27,937)
Balance at March 31, 2026	60,310,526	$	60	$	647,714	$	(263)	$	(473,842)	$	173,669
Exercises of stock options	105,481		—		57		—		—		57
Vesting of restricted stock units	55,914		—		—		—		—		—
Issuance of common stock under ESPP	73,473		—		219		—		—		219
Issuance of common stock from at-the-market sales agreement, net of issuance costs	727,996		1		2,629		—		—		2,630
Stock-based compensation expense	—		—		2,433		—		—		2,433
Unrealized loss on available-for-sale securities, net of tax	—		—		—		(158)		—		(158)
Net loss	—		—		—		—		(24,473)		(24,473)
Balance at June 30, 2026	61,273,390	$	61	$	653,052	$	(421)	$	(498,315)	$	154,377
Vesting of restricted stock units	21,769		—		—		—		—		—
Issuance of common stock from at-the-market sales agreement, net of issuance costs	878,306		1		3,032		—		—		3,033
Stock-based compensation expense	—		—		2,603		—		—		2,603
Unrealized loss on available-for-sale securities, net of tax	—		—		—		(208)		—		(208)
Net loss	—		—		—		—		(24,694)		(24,694)
Balance at September 30, 2026	62,173,465	$	62	$	658,687	$	(629)	$	(523,009)	$	135,111

Accumulated
Additional · Other
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balance at December 31, 2024	54,731,316	$	55	$	626,296	$	(407)	$	(326,184)	$	299,760
Exercises of stock options	27,613		—		82		—		—		82
Vesting of restricted stock units	450,556		—		—		—		—		—
Stock-based compensation expense	—		—		3,673		—		—		3,673
Unrealized gain on available-for-sale securities, net of tax	—		—		—		208		—		208
Net loss	—		—		—		—		(31,021)		(31,021)
Balance at March 31, 2025	55,209,485	$	55	$	630,051	$	(199)	$	(357,205)	$	272,702
Exercises of stock options	27,433		1		78		—		—		79
Vesting of restricted stock units	99,528		—		—		—		—		—
Issuance of common stock under ESPP	98,510		—		434		—		—		434
Stock-based compensation expense	—		—		4,133		—		—		4,133
Unrealized loss on available-for-sale securities, net of tax	—		—		—		(22)		—		(22)
Net loss	—		—		—		—		(33,382)		(33,382)
Balance at June 30, 2025	55,434,956	$	56	$	634,696	$	(221)	$	(390,587)	$	243,944
Exercises of stock options	29,059		—		85		—		—		85
Vesting of restricted stock units	18,247		—		—		—		—		—
Stock-based compensation expense	—		—		3,460		—		—		3,460
Unrealized gain on available-for-sale securities, net of tax	—		—		—		228		—		228
Net loss	—		—		—		—		(27,892)		(27,892)
Balance at September 30, 2025	55,482,262	$	56	$	638,241	$	7	$	(418,479)	$	219,825

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.